RxDoctor Payments Data

Patricia Nibler, MD

Internal Medicine · Bend, ORNPI 1386708873

Payments from drug & device makers

$451in general payments, 2019–2025

Across 24 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$123
  • Amgen$97
  • Gilead$81
  • Medtronic$57
  • Novo Nordisk$49
  • Kowa Pharmaceuticals America, Inc.$19
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$43496%
  • Education$164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie6$123
Amgen6$97
Gilead4$81
Medtronic(2 entities)2$57
Novo Nordisk3$49
Kowa Pharmaceuticals America, Inc.1$19
Nestle Healthcare Nutrition Inc.1$16
Linus Health, Inc.1$9

How this compares

$451 in reported general payments places this provider in the 85th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$161,088
Medicare patients
251
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$117,326
JardianceEmpagliflozin49$57,479
MounjaroTirzepatide42$48,450
OzempicSemaglutide21$29,197
XareltoRivaroxaban32$27,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,430
EstringEstradiol26$13,443
Repatha SureclickEvolocumab14$12,609
Arnuity ElliptaFluticasone Furoate15$6,211
Estradiol47$3,506
Candesartan Cilexetil39$3,139
Ezetimibe79$3,132
Rosuvastatin Calcium180$3,121
Levothyroxine Sodium307$3,068
PaxlovidNirmatrelvir/Ritonavir19$2,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$29,19721 claims
AbbVieSynthroid$123$2,15283 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →